Gavreto (pralsetinib) — Medica
Anaplastic Thyroid Cancer
Initial criteria
- Patient is age ≥ 12 years
- Patient has unresectable, recurrent, or metastatic disease
- Patient has rearranged during transfection (RET) fusion-positive or RET-mutation-positive disease
Approval duration
1 year